Diffuse large B-cell lymphoma
M Martelli, AJM Ferreri, C Agostinelli, A Di Rocco… - Critical reviews in …, 2013 - Elsevier
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults
accounting for 31% of all NHL in Western Countries. Following, morphological, biological …
accounting for 31% of all NHL in Western Countries. Following, morphological, biological …
A molecular perspective on rituximab: a monoclonal antibody for B cell non Hodgkin lymphoma and other affections
N Seyfizadeh, N Seyfizadeh, J Hasenkamp… - Critical reviews in …, 2016 - Elsevier
Rituximab (a chimeric anti-CD20 monoclonal antibody) is the first Food and Drug
Administration approved anti-tumor antibody. Immunotherapy by rituximab, especially in …
Administration approved anti-tumor antibody. Immunotherapy by rituximab, especially in …
A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive …
A Tucci, S Ferrari, C Bottelli, E Borlenghi… - … Journal of the …, 2009 - Wiley Online Library
BACKGROUND: The authors set out to analyze if a simple comprehensive geriatric
assessment (CGA) could objectively identify elderly patients with diffuse large cell …
assessment (CGA) could objectively identify elderly patients with diffuse large cell …
High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for follicular lymphoma in adults
M Schaaf, M Reiser, P Borchmann… - Cochrane Database …, 2012 - cochranelibrary.com
Background Follicular lymphoma (FL) is the most common indolent and second most
common Non‐Hodgkins lymphoma (NHL) in the Western world. Standard treatment usually …
common Non‐Hodgkins lymphoma (NHL) in the Western world. Standard treatment usually …
Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden
F Kasteng, M Erlanson, H Hagberg, E Kimby… - Acta …, 2008 - Taylor & Francis
Introduction. Rituximab has significantly improved the prognosis for patients with both
indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out …
indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out …
[HTML][HTML] Comparison of ifosfamide, carboplatin and etoposide versus etoposide, steroid, and cytarabine cisplatin as salvage chemotherapy in patients with refractory …
Background: Refractory or relapsed Hodgkin's disease (HD) occurs in 10-50% of patients.
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …
Clinical features and prognostic factors of primary bone marrow lymphoma
G Wang, Y Chang, X Wu, X Li, L Li… - Cancer Management …, 2019 - Taylor & Francis
Background Primary bone marrow lymphoma (PBML) is a very uncommon neoplasm
originally arising in the bone marrow system, and the most common pathological type is …
originally arising in the bone marrow system, and the most common pathological type is …
Hyper-CVAD/MA 方案治疗复发或难治性非霍奇金淋巴瘤临床分析
王伟， 周学义， 薛玉宝， 朱子元， 史会昌， 刘淮东， 杨飞 - 现代肿瘤医学, 2010 - cqvip.com
目的: 评价hyper-CVAD/MA 方案治疗复发或难治性非霍奇金淋巴瘤的疗效, 安全性和不良反应.
方法: 24 例复发或难治性非霍奇金淋巴瘤患者采用hyper-CVAD/MA 方案治疗. 化疗每28 …
方法: 24 例复发或难治性非霍奇金淋巴瘤患者采用hyper-CVAD/MA 方案治疗. 化疗每28 …
Hyper-CVAD/MA 方案治疗高度侵袭性非霍奇金淋巴瘤临床观察
潘佳， 李国杰， 丁辉， 程传耀 - 中国当代医药, 2012 - cqvip.com
目的观察Hyper—CVAD/MA 方案治疗高度侵袭性非霍奇金淋巴瘤疗效及毒副反应.
方法选取高度侵袭性非霍奇金淋巴瘤患者12 例. 予以Hyper—CVAD/MA 方案治疗, Hyper …
方法选取高度侵袭性非霍奇金淋巴瘤患者12 例. 予以Hyper—CVAD/MA 方案治疗, Hyper …
Hyper-CVAD 方案治疗22 例侵袭性和高度侵袭性非霍奇金淋巴瘤疗效分析
徐卫， 李建勇， 张苏江， 钱思轩， 许戟， 吴汉新， 陆化… - 中华血液学杂志, 2007 - cqvip.com
Hyper-CVAD方案治疗22例侵袭性和高度侵袭性非霍奇金淋巴瘤疗效分析-[维普官方网站]-www.cqvip.com-维普
网 我的维普 购物车 充值 客服 首页 | 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 …
网 我的维普 购物车 充值 客服 首页 | 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 …